Zacks Investment Research · May 6, 2024
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
AA
NASDAQ · AADI
Aadi Bioscience, Inc.
Healthcare · Biotechnology
$2.05
Down-$0.05 (-2.38%)
Updated Sep 17, 2026, 7:28 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.89M
- P/E ratio
- -15.34
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 62.61K
- Avg. volume
- 200.71K
Price performance
AADI price history
1M range · 0 trading sessions · Daily adjusted prices
AADI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest AADI news
The latest Smart Investors Daily articles mentioning AADI.
Stock researchCompany · Overview
AADI research
Overview
Company profile and research snapshot.
Company profile
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.63
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2024 | Piper Sandler | Neutral | — |
| Aug 21, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 21, 2024 | TD Cowen | Hold | — |
| May 14, 2024 | HC Wainwright & Co. | Neutral | — |
| Dec 15, 2023 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Apr 3, 2024
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Zacks Investment Research · Mar 18, 2024
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Zacks Investment Research · Mar 11, 2024
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
